Russell Investments Group’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-12,625
| Closed | -$272K | – | 4241 |
|
|
2025
Q4 | $272K | Buy |
12,625
+967
| +8% | +$18.8K | ﹤0.01% | 2724 |
|
|
2025
Q3 | $178K | Buy |
11,658
+3,646
| +46% | +$47.4K | ﹤0.01% | 2850 |
|
|
2025
Q2 | $70.9K | Sell |
8,012
-112
| -1% | -$984 | ﹤0.01% | 2904 |
|
|
2025
Q1 | $63.6K | Sell |
8,124
-120,117
| -94% | -$1.01M | ﹤0.01% | 2850 |
|
|
2024
Q4 | $1.35M | Buy |
128,241
+11,350
| +10% | +$138K | ﹤0.01% | 1859 |
|
|
2024
Q3 | $1.53M | Buy |
116,891
+116,413
| +24,354% | +$1.77M | ﹤0.01% | 1825 |
|
|
2024
Q2 | $6.72K | Sell |
478
-114,563
| -100% | -$1.87M | ﹤0.01% | 3160 |
|
|
2024
Q1 | $1.94M | Buy |
+115,041
| New | +$1.71M | ﹤0.01% | 1665 |
|
|
2020
Q3 | – | Sell |
-61,986
| Closed | -$499K | – | 3180 |
|
|
2020
Q2 | $499K | Buy |
+61,986
| New | +$546K | ﹤0.01% | 2380 |
|
|
2018
Q2 | – | Sell |
-5,052
| Closed | -$37K | – | 2896 |
|
|
2018
Q1 | $37K | Sell |
5,052
-19,222
| -79% | -$169K | ﹤0.01% | 2850 |
|
|
2017
Q4 | $199K | Sell |
24,274
-424,512
| -95% | -$3.98M | ﹤0.01% | 2671 |
|
|
2017
Q3 | $4.71M | Sell |
448,786
-10,994
| -2% | -$105K | 0.01% | 1303 |
|
|
2017
Q2 | $5.07M | Buy |
459,780
+82,340
| +22% | +$827K | 0.01% | 1233 |
|
|
2017
Q1 | $3.65M | Buy |
377,440
+48,201
| +15% | +$482K | 0.01% | 1406 |
|
|
2016
Q4 | $3.31M | Buy |
+329,239
| New | +$3.62M | 0.01% | 1508 |
|
Other funds holding AVDL
Russell Investments Group's AVDL Position: Q1 2026 in Review
Russell Investments Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 12,625 shares — an estimated $272K sold.
Russell Investments Group first reported a position in AVDL in Q4 2016 and held it in 15 quarters. The position peaked at $5.07M in Q2 2017. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Russell Investments Group reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Russell Investments Group sold 12,625 Avadel Pharmaceuticals shares in Q1 2026, an estimated $272K.
- Russell Investments Group first reported a position in Avadel Pharmaceuticals in Q4 2016 and held it in 15 quarters.
- Russell Investments Group's Avadel Pharmaceuticals position peaked at $5.07M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.